arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Stereotaxis, Inc.

STXS
$1.42 ▲ +0.06 (+4.41%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
18 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

Stereotaxis, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $129.2M
Dividend Yield
Revenue Growth 20.3%
Op. Margin -68.3%
ROIC -129.6%
FCF / Share $-0.15
Trailing P/E
Price / Book 9.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$32.38M
↑ +20.3%
Net Income Profit after all expenses
$-21.64M
↑ +10.0%
Operating Margin Operating profit as % of sales
-68.3%
↑ +25.7% 4th
FCF / Share Free cash flow per share
$-0.15
↓ -50.8%
Long-Term Debt Long-term obligations
$973.25K
↓ -94.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
4
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters